Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 133

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 133
---
 we believe there are adequate options and time available to secure additional financing for us and after considering the
uncertainties, we consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements.

Our
forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement
and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical
trials. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner
than we currently expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities,
our business, financial condition and results of operations could be materially adversely affected.

Cash Flows

The following table presents a summary
of the primary sources and uses of cash from continuing activities for the six months ended June 30, 2024 and 2023 and the years ended
December 31, 2023 and 2022:

|                                                                |     | Six Months Ended June 30,  
 2024                       |        |   |     | 2023 |        |   |     | Year Ended December 31, 
 2023                    |        |   |     | 2022 |        |   |
|:---------------------------------------------------------------|:----|:---------------------------|-------:|:--|:----|:-----|-------:|:--|:----|:------------------------|-------:|:--|:----|:-----|-------:|:--|
|                                                                |     | -£ in thousands; unaudited |        |   |     |      |        |   |     | -£ in thousands         |        |   |     |      |        |   |
| Cash used in operating activities                              |     |                            | (4,807 | ) |     |      | (3,881 | ) |     |                         | (6,826 | ) |     |      | (7,048 | ) |
| Cash generated from/(used in) provided by investing activities |     |                            |   (754 | ) |     |      |     20 |   |     |                         |   (265 | ) |     |      |   (220 | ) |
| Cash generated from/(used in) provided by financing activities |     |                            |  4,645 |   |     |      |  6